Peer-reviewed validation study, expanding institutional adoption, and human-centered innovation reinforce Mentavi's leadership in mental health care GRAND RAPIDS, MI /...
• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’...
- TRPML1 is a promising target1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement in...
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in...
Nugevia™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss Jupiter, Florida, Jan. 28, 2026 (GLOBE NEWSWIRE) --...
Actor and comedian, Will Forte, opens up about his brother-in-law's journey with Huntington’s disease (HD) and chorea through Teva’s Honestly...
BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the...
HONG KONG, Jan. 26, 2026 /PRNewswire/ -- Prof. Nancy IP, President of The Hong Kong University of Science and Technology (HKUST),...
Peer-reviewed research by Dr Joe Dispenza and HeartMath Institute reveals measurable global effects of emotionally coherent group meditationSAN DIEGO, Jan. 23,...
Peer-reviewed research by Dr Joe Dispenza and HeartMath Institute reveals measurable global effects of emotionally coherent group meditationSAN DIEGO, Jan. 23,...
WILMINGTON, Mass., Jan. 23, 2026 /PRNewswire/ -- Analog Devices, Inc. (Nasdaq: ADI) today announced the appointment of Dr. Yoky Matsuoka to...
PLEASANTON, Calif., Jan. 22, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it...
Ignites 2026 with new ski-focused series from Dr. Tom LankeringNEW BERN, N.C., Jan. 22, 2026 /PRNewswire/ -- BrainTap, the leading provider...
Cortigent is a leading developer of brain interface devices based on precision neurostimulation technology The company’s new Orion cortical stimulation...
Investigational ARC-BCI® Therapy is being developed to restore thought-driven movement in people living with spinal cord injuries and other movement...
Panelists include leaders in the fields of science, medicine and technology: Jack Hidary, Dr. Edward Neilan, Dr. Shoshana Shendelman, Dr....
New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patientsBURLINGTON, Mass. and JERUSALEM,...
DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical...
EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies and participating Aytu...
Series B financing will support Exciva's Phase 2 clinical trial of its lead candidate, Deraphan, for agitation associated with Alzheimer's...